← Search & browse all drugs

interferon beta-1a

L03AB07

Forms & Strengths

Prefilled syringes: 22 mcg/0.5 mL, 30 mcg/0.5 mL, 44 mcg/0.5 mL
Prefilled pens: 22 mcg/0.5 mL, 44 mcg/0.5 mL
Lyophilized powder for injection: 30 mcg per vial

Adult Dosing

Relapsing multiple sclerosis: 30 mcg intramuscularly once weekly
Relapsing multiple sclerosis: 22 mcg or 44 mcg subcutaneously three times weekly
Titration: Initiate at lower doses (e.g., 8.8 mcg SC 3x/week) and increase over 4 weeks to target dose to reduce flu-like symptoms

Pediatric Dosing

Safety and efficacy not established in pediatric patients below 12 years of age
Pediatric patients aged 12 to 17 years: 22 mcg or 44 mcg subcutaneously three times weekly, or 30 mcg intramuscularly once weekly

Indications

Treatment of relapsing forms of multiple sclerosis (MS) to slow the accumulation of physical disability and decrease frequency of clinical exacerbations
Clinically isolated syndrome (CIS) in patients with a first clinical episode and MRI features consistent with multiple sclerosis

Mechanism of Action

Recombinant interferon beta that binds to specific cell surface receptors, initiating a cascade of intracellular events
Upregulates expression of interferon-stimulated genes, downregulates expression of pro-inflammatory cytokines, and reduces antigen presentation
Reduces blood-brain barrier permeability and suppresses T-cell proliferation, reducing inflammatory central nervous system activity

Contraindications

Hypersensitivity to natural or recombinant interferon beta or human albumin
Severe depressive illness and/or suicidal ideation

Adverse Reactions

Flu-like syndrome (myalgia, fever, chills, fatigue, headache, nausea)
Injection site reactions (erythema, pain, necrosis)
Hepatic injury (elevated transaminases, autoimmune hepatitis, severe liver failure)
Depression, suicidal ideation, and anxiety
Leukopenia, lymphopenia, and anemia
Seizures and thrombotic microangiopathy

Drug Interactions

Cytochrome P450 inducers/inhibitors: Theoretical risk of altering metabolism, though interferon beta is not known to be a significant CYP substrate or inhibitor
Myelosuppressive agents: May increase risk of bone marrow suppression and cytopenias when used concomitantly
Other hepatotoxic medications: Potential for additive hepatotoxicity

Curated Content: Needs Vetting Before Put to Clinical Use